- Homepage
-
Formulary Home
-
1 Gastro-intestinal system
- 1.1 Dyspepsia and gastro-oesophageal reflux disease
- 1.2 Antispasmodics and other drugs altering gut motility
- 1.3 Antisecretory drugs and mucosal protectants
- 1.4 Acute diarrhoea
-
1.5 Chronic bowel disorders
- 1.5.1 Aminosalicylates
- 1.5.2 Corticosteroids
-
1.5.3 Drugs affecting the immune response
- Ulcerative colitis (acute exacerbations) - infliximab - NICE TAG TA163
- Crohn's disease - infliximab (review) and adalimumab (review of TA40) - NICE TAG TA187
- Ulcerative colitis (subacute manifestations) - infliximab - NICE TAG TA140
- Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) - NICE TAG TA329
- Vedolizumab for treating moderately to severely active ulcerative colitis - NICE TAG TA342
- Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy - NICE TAG TA352
- Tofacitinib for moderately to severely active ulcerative colitis - NICE TAG TA547
- 1.5.4 Food allergy
- 1.6 Laxatives
- 1.7 Local preparations for anal and rectal disorders
- 1.8 Stoma care
- 1.9 Drugs affecting intestinal secretions
-
2 Cardiovascular system
- 2.1 Positive inotropic drugs
- 2.2 Diuretics
- 2.3 Anti-arrhythmic drugs
- 2.4 Beta-adrenoceptor blocking drugs
- 2.5 Hypertension and heart failure
- 2.6 Nitrates, calcium-channel blockers, and other antianginal drugs
- 2.7 Sympathomimetics
-
2.8 Anticoagulants and protamine
- 2.8.1 Parenteral anticoagulants
-
2.8.2 Oral anticoagulants
- Atrial fibrillation - dabigatran etexilate - NICE TAG TA249
- Atrial fibrillation (stroke prevention) - rivaroxaban - NICE TAG TA256
- Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban - NICE TAG TA287
- Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban - NICE TAG TA275
- Venous thromboembolism - dabigatran - NICE TAG TA157
- Venous thromboembolism (hip and knee surgery) - apixaban - NICE TAG TA245
- Venous thromboembolism - rivaroxaban - NICE TAG TA170
- Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban - NICE TAG TA261
- Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism - NICE TAG TA327
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome - NICE TAG TA335
- Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism - NICE TAG TA341
- Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation - NICE TAG TA355
- Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism - NICE TAG TA354
- 2.8.3 Protamine sulfate
-
2.9 Antiplatelet drugs
- Acute coronary syndrome - prasugrel - NICE TAG TA182
- Vascular disease - clopidogrel and dipyridamole - NICE TAG TA210
- Acute coronary syndromes - ticagrelor - NICE TAG TA236
- Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) - NICE TAG TA317
- Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) - NICE TAG TA351
- Ticagrelor for preventing atherothrombotic events after myocardial infarction - NICE TAG TA420
- 2.10 Stable angina, acute coronary syndromes, and fibrinolysis
- 2.11 Antifibrinolytic drugs and haemostatics
-
2.12 Lipid-regulating drugs
- Cardiovascular disease - statins - NICE TAG TA94
- Hypercholesterolaemia - ezetimibe - NICE TAG TA132
- Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia - NICE TAG TA385
- Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia - NICE TAG TA385
- Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia - NICE TAG TA394
- Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia - NICE TAG TA393
- 2.13 Local sclerosants
- 2.14 Other cardiovascular drugs
-
3 Respiratory system
- 3.1 Bronchodilators
- 3.2 Corticosteroids
- 3.3 Cromoglicate and related therapy, leukotriene receptor antagonists, and phosphodiesterase type-4 inhibitors
-
3.4 Antihistamines, hyposensitisation, and allergic emergencies
- 3.4.1 Antihistamines
-
3.4.2 Allergen immunotherapy
- Venom anaphylaxis - immunotherapy pharmalgen - NICE TAG TA246
- Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) - NICE TAG TA278
- Omalizumab for previously treated chronic spontaneous urticaria - NICE TAG TA339
- Mepolizumab for treating severe refractory eosinophilic asthma - NICE TAG TA431
- Reslizumab for treating severe eosinophilic asthma - NICE TAG TA479
- Benralizumab for treating severe eosinophilic asthma - NICE TAG TA565
- 3.4.3 Allergic emergencies
- 3.5 Respiratory stimulants and pulmonary surfactants
- 3.6 Oxygen
- 3.7 Mucolytics
- 3.8 Aromatic inhalations
- 3.9 Cough preparations
- 3.10 Systemic nasal decongestants
- 3.11 Antifibrotics
- 3.12 Miscellaneous
-
4 Central nervous system
- 4.1 Hypnotics and anxiolytics
- 4.2 Drugs used in psychoses and related disorders
- 4.3 Antidepressant drugs
- 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
- 4.5 Drugs used in the treatment of obesity
- 4.6 Drugs used in nausea and vertigo
- 4.7 Analgesics
- 4.8 Antiepileptic drugs
- 4.9 Drugs used in parkinsonism and related disorders
- 4.10 Drugs used in substance dependence
- 4.11 Drugs for dementia
-
5 Infections
-
5.1 Antibacterial drugs
- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, carbapenems, and other beta-lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other antibacterials
- 5.1.8 Sulfonamides and trimethoprim
- 5.1.9 Antituberculosis drugs
- 5.1.10 Antileprotic drugs
- 5.1.11 Metronidazole and tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract infections
- 5.2 Antifungal drugs
-
5.3 Antiviral drugs
- 5.3.1 HIV infection
- 5.3.2 Herpesvirus infections
-
5.3.3 Viral hepatitis
- 5.3.3.1 Chronic hepatitis B
-
5.3.3.2 Chronic hepatitis C
- Hepatitis C - peginterferon alfa and ribavirin - NICE TAG TA200
- Hepatitis C (genotype 1) - telaprevir - NICE TAG TA252
- Hepatitis C (genotype 1) - boceprevir - NICE TAG TA253
- Glecaprevir–pibrentasvir for treating chronic hepatitis C - NICE TAG TA499
- Hepatitis C (children and young people) - peginterferon alfa and ribavirin NICE TAG TA300
- Sofosbuvir for treating chronic hepatitis C - NICE TAG TA330
- Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis - NICE TAG TA331
- Ledipasvir–sofosbuvir for treating chronic hepatitis C - NICE TAG TA363
- Daclatasvir for treating chronic hepatitis C - NICE TAG TA364
- Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C - NICE TAG TA365
- Elbasvir–grazoprevir for treating chronic hepatitis C - NICE TAG TA413
- Sofosbuvir–velpatasvir for treating chronic hepatitis C - NICE TAG TA430
- Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C - NICE TAG TA507
- 5.3.4 Influenza
- 5.3.5 Respiratory syncytial virus
- 5.4 Antiprotozoal drugs
- 5.5 Anthelmintics
-
5.1 Antibacterial drugs
-
6 Endocrine system
-
6.1 Drugs used in diabetes
- 6.1.1 Insulins
-
6.1.2 Antidiabetic drugs
- Type 2 diabetes in adults: management - NICE NG28
- Dapagliflozin in combination therapy for treating type 2 diabetes - NICE TAG TA288
- Canagliflozin in combination therapy for treating type 2 diabetes - NICE TAG TA315
- Empagliflozin in combination therapy for treating type 2 diabetes - NICE TAG TA336
- Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes - NICE TAG TA390
- Dapagliflozin in triple therapy for treating type 2 diabetes - NICE TAG TA418
- Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes - NICE TAG TA572
- Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes - NICE TAG TA583
- 6.1.3 Diabetic ketoacidosis
- 6.1.4 Treatment of hypoglycaemia
- 6.1.5 Treatment of diabetic nephropathy and neuropathy
- 6.1.6 Diagnostic and monitoring devices for diabetes mellitus
- 6.2 Thyroid and antithyroid drugs
- 6.3 Corticosteroids
- 6.4 Sex hormones
- 6.5 Hypothalamic and pituitary hormones and anti-oestrogens
-
6.6 Drugs affecting bone metabolism
- 6.6.1 Calcitonin and parathyroid hormone
-
6.6.2 Bisphosphonates and other drugs affecting bone metabolism
- Osteoporosis - primary prevention - NICE TAG TA160
- Osteoporosis - secondary prevention including strontium ranelate - NICE TAG TA161
- Osteoporotic fractures - denosumab - NICE TAG TA204
- Bone metastases from solid tumours – denosumab - NICE TAG TA265
- Bisphosphonates for treating osteoporosis - NICE TAG TA464
- Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) - NICE TAG TA549
- 6.7 Other endocrine drugs
-
6.1 Drugs used in diabetes
-
7 Obstetrics, gynaecology, and urinary-tract disorders
- 7.1 Drugs used in obstetrics
- 7.2 Treatment of vaginal and vulval conditions
- 7.3 Contraceptives
- 7.4 Drugs for genito-urinary disorders
-
8 Malignant disease and immunosuppression
-
8.1 Cytotoxic drugs
- 8.1.1 Alkylating drugs
- 8.1.2 Anthracyclines and other cytotoxic antibiotics
-
8.1.3 Antimetabolites
- Pancreatic cancer - gemcitabine - Nice TAG TA25
- Leukaemia (lymphocytic) - fludarabine - NICE TAG TA29
- Colorectal cancer - capecitabine and tegafur uracil - NICE TAG TA61
- Renal transplantation - immuno-suppressive regimens (adults) - NICE TAG TA85
- Colon cancer (adjuvant) - capecitabine and oxaliplatin - NICE TAG TA100
- Breast cancer - gemcitabine - NICE TAG TA116
- Leukaemia (lymphocytic) - fludarabine - NICE TAG TA119
- Lung cancer (non-small-cell) - pemetrexed - NICE TAG TA124
- Mesothelioma - pemetrexed disodium NICE TAG TA135
- Lung cancer (non-small-cell, first line treatment) - pemetrexed - NICE TAG TA181
- Lung cancer (non-small-cell) - pemetrexed (maintenance) - NICE TAG TA190
- Gastric cancer (advanced) - capecitabine - NICE TAG TA191
- Myelodysplastic syndromes - azacitidine - NICE TAG TA218
- Lung cancer (non small cell, non squamous) - pemetrexed NICE TAG TA309
- Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin - NICE TAG TA402
- Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts - NICE TAG TA399
- Cladribine tablets for treating relapsing–remitting multiple sclerosis - NICE TAG TA493
- Decitabine for untreated acute myeloid leukaemia (terminated appraisal) - NICE TAG TA548
- 8.1.4 Vinca alkaloids and etoposide
-
8.1.5 Other antineoplastic drugs
- Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) - NICE TAG TA23
- Breast cancer - trastuzumab - NICE TAG TA34
- Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block- NICE TAG TA55
- Gastrointestinal stromal tumours - imatinib - NICE TAG TA86
- Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) - NICE TAG TA91
- Prostate cancer (hormone-refractory) - docetaxel - NICE TAG TA101
- Breast cancer (early) - trastuzumab - NICE TAG TA107
- Breast cancer (early) - paclitaxel - NICE TAG TA108
- Breast cancer (early) - docetaxel - NICE TAG TA109
- Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer- NICE TAG TA118
- Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide - NICE TAG TA121
- Multiple myeloma - bortezomib - NICE TAG TA129
- Head and neck cancer - cetuximab - NICE TAG TA145
- Lung cancer (non-small-cell) - erlotinib - NICE TAG TA162
- Renal cell carcinoma - sunitinib - NICE TAG TA169
- Head and neck cancer (squamous cell carcinoma) - cetuximab - NICE TAG TA172
- Colorectal cancer (first line) - cetuximab - NICE TAG TA176
- Renal cell carcinoma - NICE TAG TA178
- Gastrointestinal stromal tumours - sunitinib - NICE TAG TA179
- Cervical cancer (recurrent) - topotecan - NICE TAG TA183
- Lung cancer (small-cell) - topotecan - NICE TAG TA184
- Soft tissue sarcoma - trabectedin - NICE TAG TA185
- Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) - NICE TAG TA189
- Lung cancer (non-small-cell, first line) - gefitinib - NICE TAG TA192
- Gastrointestinal stromal tumours - imatinib (adjuvant) - NICE TAG TA196
- Gastric cancer (HER2-positive metastatic) - trastuzumab - NICE TAG TA208
- Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib - NICE TAG TA209
- Colorectal cancer (metastatic) - bevacizumab - NICE TAG TA212
- Breast cancer - bevacizumab (in combination with a taxane) - NICE TAG TA214
- Pazopanib for the first-line treatment of advanced renal cell carcinoma - NICE TAG TA215
- Everolimus for the second-line treatment of advanced renal cell carcinoma - NICE TAG TA219
- Ovarian cancer (relapsed) - trabectedin - NIE TAG TA222
- Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) - NICE TAG TA227
- Multiple myeloma (first line) - bortezomib and thalidomide - NICE TAG TA228
- Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) - NICE TAG TA241
- Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab - NICE TAG TA242
- Breast cancer (advanced) - eribulin - NICE TAG TA250
- Leukaemia (chronic myeloid, first line) - dasatanib, nilotinib and standard-dose imatinib - NICE TAG TA251
- Prostate cancer - cabazitazel - NICE TAG TA255
- Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) - NICE TAG TA257
- Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) - NICE TAG TA258
- Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer - NICE TAG TA263
- Melanoma (stage III or IV) - ipilimumab - NICE TAG TA268
- Melanoma (BRAF V600 mutation positive, unresectable metastatic) – vemurafenib - NICE TAG TA269
- Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer - NICE TAG TA284
- Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab - NICE TAG TA285
- Myelofibrosis (splenomegaly, symptoms) - ruxolitinib - NICE TAG TA289
- Guidance on the use of imatinib for chronic myeloid leukaemia - NICE TAG TA70
- Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) - NICE TAG TA295
- Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib NICE TAG TA296
- Leukaemia (chronic myeloid) - bosutinib NICE TAG TA299
- Macular oedema (central retinal vein occlusion) - aflibercept solution for injection NICE TAG TA305
- Colorectal cancer (metastatic) - aflibercept NICE TAG TA307
- Lung cancer (non small cell, EGFR mutation positive) - afatinib NICE TAG TA310
- Multiple myeloma - bortezomib (induction therapy) NICE TAG TA311
- Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma - NICE TAG TA319
- Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma - NICE TAG TA321
- Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196) - NICE TAG TA326
- Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment - NICE TAG TA333
- Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG TA357
- Ruxolitinib for treating polycythaemia vera (terminated appraisal) - NICE TAG 356
- Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) - NICE TAG TA353
- Aflibercept for treating diabetic macular oedema - NICE TAG TA346
- Everolimus for preventing organ rejection in liver transplantation - NICE TAG TA348
- Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer - NICE TAG TA347
- Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) - NICE TAG TA334
- Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) - NICE TAG TA328
- Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG 357
- Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) - NICE TAG TA362
- Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer - NICE TAG TA360
- Idelalisib for treating chronic lymphocytic leukaemia - NICE TAG TA359
- Pembrolizumab for advanced melanoma not previously treated with ipilimumab - NICE TAG TA366
- Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane - NICE TAG TA371
- Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy - NICE TAG TA374
- Bortezomib for previously untreated mantle cell lymphoma - NICE TAG TA370
- Nintedanib for treating idiopathic pulmonary fibrosis - NICE TAG TA379
- Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy - NICE TAG TA378
- Panobinostat for treating multiple myeloma after at least 2 previous treatments - NICE TAG TA380
- Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy - NICE TAG TA381
- Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis - NICE TAG TA386
- Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer - NICE TAG TA389
- Nivolumab for treating advanced (unresectable or metastatic) melanoma - NICE TAG TA384
- Bosutinib for previously treated chronic myeloid leukaemia - NICE TAG TA401
- Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer - NICE TAG TA403
- Nivolumab in combination with ipilimumab for treating advanced melanoma - NICE TAG TA400
- Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma - NICE TAG TA396
- Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel - NICE TAG TA391
- Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer - NICE TAG TA395
- Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA406
- Pegaspargase for treating acute lymphoblastic leukaemia - NICE TAG TA408
- Talimogene laherparepvec for treating unresectable metastatic melanoma - NICE TAG TA410
- Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer - NICE TAG TA411
- Trifluridine–tipiracil for previously treated metastatic colorectal cancer - NICE TAG TA405
- Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma - NICE TAG TA414
- Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer - NICE TAG TA416
- Nivolumab for previously treated advanced renal cell carcinoma - NICE TAG TA417
- Everolimus with exemestane for treating advanced breast cancer after endocrine therapy - NICE TAG TA421
- Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA422
- Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens - NICE TAG TA423
- Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer - NICE TAG TA424
- Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia - NICE TAG TA425
- Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia - NICE TAG TA426
- Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy- NICE TAG TA428
- Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440
- Cetuximab and panitumumab for previously untreated metastatic colorectal cancer - NICE TAG TA439
- Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation - NICE TAG TA429
- Everolimus for advanced renal cell carcinoma after previous treatment - NICE TAG TA432
- Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA462
- Carfilzomib for previously treated multiple myeloma - NICE TAG TA457
- Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane - NICE TAG TA458
- Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) - NICE TAG TA452
- Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) - NICE TAG TA453
- Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) - NICE TAG TA453
- Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma - NICE TAG TA446
- Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer - NICE TAG TA447
- Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease - NICE TAG TA449
- Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia - NICE TAG451
- Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) - NICE TAG TA444
- Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440
- Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA540
- Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine - NICE TAG TA535
- Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) - NICE TAG TA469
- Cabozantinib for previously treated advanced renal cell carcinoma - NICE TAG TA463
- Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer - NICE TAG TA476
- Sorafenib for treating advanced hepatocellular carcinoma - NICE TAG TA474
- Ibrutinib for treating Waldenstrom’s macroglobulinaemia - NICE TAG TA491
- Vismodegib for treating basal cell carcinoma - NICE TAG TA489
- Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours - NICE TAG TA488
- Venetoclax for treating chronic lymphocytic leukaemia - NICE TAG TA487
- Ibrutinib for treating relapsed or refractory mantle cell lymphoma - NICE TAG TA502
- Ceritinib for untreated ALK-positive non-small-cell lung cancer - NICE TAG TA500
- Lenvatinib with everolimus for previously treated advanced renal cell carcinoma - NICE TAG TA498
- Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma - NICE TAG TA505
- Cabozantinib for treating medullary thyroid cancer - NICE TAG TA516
- Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen - NICE TAG TA515
- Regorafenib for previously treated advanced hepatocellular carcinoma - NICE TAG TA514
- Daratumumab monotherapy for treating relapsed and refractory multiple myeloma - NICE TAG TA510
- Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer - NICE TAG TA509
- Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NICE TAG TA519
- Avelumab for treating metastatic Merkel cell carcinoma - NICE TAG TA517
- Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy - NICE TAG TA520
- Arsenic trioxide for treating acute promyelocytic leukaemia - NICE TAG TA526
- Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NICE TAG TA525
- Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma - NICE TAG TA524
- Midostaurin for untreated acute myeloid leukaemia - NICE TAG TA523
- Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable - NICE TAG TA522
- Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer - NICE TAG TA531
- Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy - NICE TAG TA530
- Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer - NICE TAG TA529
- Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer - NIE TAG TA528
- Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours - NICE TAG TA539
- Dinutuximab beta for treating neuroblastoma - NICE TAG TA538
- Alectinib for untreated ALK-positive advanced non-small-cell lung cancer - NICE TAG TA536
- Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine - NICE TAG TA535
- Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia - NICE TAG TA541
- Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA540
- Cabozantinib for untreated advanced renal cell carcinoma - NICE TAG TA542
- Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma - NICE TAG TA544
- Gemtuzumab ozogamicin for untreated acute myeloid leukaemia - NICE TAG TA545
- Vandetanib for treating medullary thyroid cancer - NICE TAG TA550
- Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer - NICE TAG TA557
- Regorafenib for previously treated advanced hepatocellular carcinoma - NICE TAG TA555
- Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence - NICE TAG TA553
- Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years - NICE TAG TA554
- Lenvatinib for untreated advanced hepatocellular carcinoma - NICE TAG TA551
- Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) - NICE TAG TA560
- Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) - NICE TAG TA 564
- Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA563
- Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma - NICE TAG TA562
- Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia - NICE TAG TA561
- Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) - NICE TAG TA560
- Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib - NICE TAG TA571
- Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) - NICE TAG TA570
- Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer - NICE TAG TA569
- Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies - NICE TAG TA567
- Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies - NICE TA TAG567
- Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma - NICE TAG TA577
- Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) - NICE TAG TA576
- Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma - NICE TAG TA573
- Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) - NICE TAG TA582
- Nivolumab with ipilimumab for untreated advanced renal cell carcinoma - NICE TAG TA581
- Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy - NICE TAG TA579
- Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation - NICE TAG TA578
- Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer - NICE TAG TA584
-
8.2 Drugs affecting the immune response
- 8.2.1 Antiproliferative immunosuppressants
-
8.2.2 Corticosteroids and other immunosuppressants
- Renal transplantation - immuno-suppressive regimens (adults) - NICE TAG TA85
- Renal transplantation - immunosuppressive regimens for children and adolescents - NICE TAG TA99
- Daclizumab for treating relapsing–remitting multiple sclerosis - NICE TAG TA441
- Immunosuppressive therapy for kidney transplant in children and young people - NICE TAG TA482
- Immunosuppressive therapy for kidney transplant in adults - NICE TAG TA481
- Ocrelizumab for treating relapsing–remitting multiple sclerosis - NICE TAG TA533
- Ocrelizumab for treating primary progressive multiple sclerosis - NICE TAG TA585
-
8.2.3 Anti-lymphocyte monoclonal antibodies
- Non-Hodgkin's lymphoma - rituximab - NICE TAG TA65
- Lymphoma (follicular non-Hodgkin's) - rituximab NICE TAG TA137
- Leukaemia (chronic lymphocytic, first line) - rituximab - NICE TAG TA174
- Leukaemia (chronic lymphocytic, relapsed) - rituximab - NICE TAG TA193
- Chronic lymphocytic leukaemia - ofatumumab - NICE TAG TA202
- Lymphoma (follicular non-Hodgkin's) - rituximab - NICE TAG TA226
- Follicular lymphoma - rituximab - NICE TAG TA243
- Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) NICE TAG TA308
- Multiple sclerosis (relapsing-remitting) - alemtuzumab NICE TAG TA312
- Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia - NICE TAG TA344
- Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia - NICE TAG TA343
- Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia - TA450
- Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck - NICE TAG TA473
- Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab - NICE TAG TA472
- Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) - NICE TAG TA470
- Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma - NICE TAG TA465
- Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma - NIE TAG TA478
- Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable - NICE TAG TA492
- Obinutuzumab for untreated advanced follicular lymphoma - NICE TAG TA513
- Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity - NICE TAG TA589
-
8.2.4 Other immunomodulating drugs
- Multiple sclerosis - beta interferon and glatiramer acetate - NICE TAG TA32
- Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases - NICE TAG TA412
- Hepatitis C - pegylated interferons, ribavirin and alfa interferon - NICE TAG TA75
- Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a - NICE TAG TA96
- Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C - NICE TAG TA106
- Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases - NICE TAG TA376
- Multiple sclerosis - natalizumab - NICE TAG TA127
- Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy - NICE TAG TA171
- Multiple myeloma (first line) - bortezomib and thalidomide - NICE TAG TA228
- Osteosarcoma - mifamurtide - NICE TAG TA235
- Multiple sclerosis (relapsing-remitting) - fingolimod - NICE TAG TA254
- Multiple sclerosis (relapsing) - teriflunomide NICE TAG TA303
- Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis - NICE TAG TA320
- Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality - NICE TAG TA322
- Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib - NICE TAG TA338
- Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib - NICE TAG TA427
- Dimethyl fumarate for treating moderate to severe plaque psoriasis - TAG TA475
- Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy - NICE TAG TA490
- Nivolumab for previously treated non-squamous non-small-cell lung cancer - NICE TAG TA484
- Nivolumab for previously treated squamous non-small-cell lung cancer - NICE TAG TA483
- Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA462
- Intrabeam radiotherapy system for adjuvant treatment of early breast cancer - NICE TAG TA501
- Tivozanib for treating advanced renal cell carcinoma - NICE TAG TA512
- Beta interferons and glatiramer acetate for treating multiple sclerosis - NICE TAG TA527
- Padeliporfin for untreated localised prostate cancer - NICE TAG TA546
- Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease - NICE TAG TA558
- Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies - NICE TAG TA559
- Lenalidomide plus dexamethasone for previously untreated multiple myeloma - NICE TAG TA587
-
8.3 Sex hormones and hormone antagonists in malignant disease
- 8.3.1 Oestrogens
- 8.3.2 Progestogens
- 8.3.3 Androgens
-
8.3.4 Hormone antagonists
- 8.3.4.1 Breast Cancer
-
8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists
- Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen- NICE TAG TA259
- Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen - NICE TAG TA316
- Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - NICE TAG TA377
- Degarelix for treating advanced hormone-dependent prostate cancer - NICE TAG TA404
- Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - NICE TAG TA387
- Enzalutamide for hormone-relapsed non-metastatic prostate cancer - NICE TAG TA580
- 8.3.4.3 Somatostatin analogues
-
8.1 Cytotoxic drugs
-
9 Nutrition and blood
-
9.1 Anaemias and some other blood disorders
- 9.1.1 Iron-deficiency anaemias
- 9.1.2 Drugs used in megaloblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias
-
9.1.4 Drugs used in platelet disorders
- Thrombocytopenic purpura - eltrombopag - NICE TAG TA205
- Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura - NICE TAG TA221
- Thrombocytopenic purpura - eltrombopag - NICE TAG TA293
- Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) - NICE TAG TA382
- 9.1.5 G6PD deficiency
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells
- 9.2 Fluids and electrolytes
- 9.3 Intravenous nutrition
- 9.4 Oral nutrition
- 9.5 Minerals
- 9.6 Vitamins
- 9.7 Bitters and tonics
- 9.8 Metabolic disorders
-
9.1 Anaemias and some other blood disorders
-
10 Musculoskeletal and joint diseases
-
10.1 Drugs used in rheumatic diseases and gout
- 10.1.1 Non-steroidal anti-inflammatory drugs
- 10.1.2 Corticosteroids
-
10.1.3 Drugs that suppress the rheumatic disease process
- Arthritis (juvenile idiopathic) - etanercept - NICE TAG TA35
- Rheumatoid arthritis - adalimumab, etanercept and infliximab - NICE TAG TA130
- Ankylosing spondylitis - adalimumab, etanercept and infliximab- NICE TAG TA143
- Rheumatoid arthritis - certolizumab pegol - NICE TAG TA186
- Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor - NICE TAG TA195
- Psoriatic arthritis - etanercept, infliximab and adalimumab - NICE TAG TA199
- Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs - NICE TAG445
- Psoriatic arthritis - golimumab - NICE TAG TA220
- Rheumatoid arthritis (after failure of previous anti-rheumatic drugs) - golimumab - NICE TAG TA225
- Ankylosing spondylitis - golimumab - NICE TAG TA233
- Arthritis (juvenile idiopathic, systemic) - tocilizumab - NICE TAG TA238
- Rheumatoid arthritis - tocilizumab - NICE TAG TA247
- Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234) - NICE TAG TA280
- Psoriatic arthritis (active) - ustekinumab NICE TAG TA313
- Apremilast for treating active psoriatic arthritis - NICE TAG TA372
- Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis - NICE TAG TA373
- Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed - NICE TAG TA375
- TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis - NICE TAG TA 383
- Belimumab for treating active autoantibody-positive systemic lupus erythematosus - NICE TAG TA397
- Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors - NICE TAG TA407
- Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor - NICE TAG TA415
- Apremilast for treating active psoriatic arthritis - NICE TAG TA433
- Ustekinumab for moderately to severely active Crohn’s disease after previous treatment - NICE TAG TA456
- Baricitinib for moderate to severe rheumatoid arthritis - NICE TAG TA466
- Tofacitinib for moderate to severe rheumatoid arthritis - NICE TAG TA480
- Sarilumab for moderate to severe rheumatoid arthritis - NICE TAG TA485
- Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA496
- Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA495
- Golimumab for treating non-radiographic axial spondyloarthritis - NICE TAG TA497
- Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee - NICE TAG TA508
- Tocilizumab for treating giant cell arteritis - NICE TAG TA518
- Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs - NICE TAG TA543
- Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) - NICE TAG TA568
- Tildrakizumab for treating moderate to severe plaque psoriasis - NICE TAG TA575
- Certolizumab pegol for treating moderate to severe plaque psoriasis - NICE TAG TA574
- 10.1.4 Gout and cytotoxic-induced hyperuricaemia
- 10.1.5 Other drugs for rheumatic diseases
- 10.2 Drugs used in neuromuscular disorders
- 10.3 Drugs for the treatment of soft-tissue disorders and topical pain relief
- Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee - NICE TAG TA477
-
10.1 Drugs used in rheumatic diseases and gout
-
11 Eye
- 11.1 Administration of drugs to the eye
- 11.2 Control of microbial contamination
- 11.3 Anti-infective eye preparations
-
11.4 Corticosteroids and other anti-inflammatory preparations
-
11.4.1 Corticosteroids
- Macular oedema (retinal vein occlusion) - dexamethasone - NICE TAG TA229
- Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) NICE TAG TA301
- Dexamethasone intravitreal implant for treating diabetic macular oedema - NICE TAG TA349
- Cenegermin for treating neurotrophic keratitis - NICE TAG TA532
- Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis - NICE TAG TA590
- 11.4.2 Other anti-inflammatory preparations
-
11.4.1 Corticosteroids
- 11.5 Mydriatics and cycloplegics
- 11.6 Treatment of glaucoma
- 11.7 Local anaesthetics
-
11.8 Miscellaneous ophthalmic preparations
- 11.8.1 Tear deficiency, ocular lubricants, and astringents
-
11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment
- Macular degeneration (age-related) - photodynamic therapy - NICE TAG TA68
- Holoclar for treating limbal stem cell deficiency after eye burns - NICE TAG TA467
- Ranibizumab and pegaptanib for the treatment of age-related macular degeneration - NICE TAG TA155
- Aflibercept for treating choroidal neovascularisation - NICE TAG TA486
- Macular oedema (diabetic) - ranibizumab - NICE TAG TA274
- Macular oedema (retinal vein occlusion) - ranibizumab - NICE TAG TA283
- Macular degeneration (wet age-related) - aflibercept (1st line) - NICE TAG TA294
- Vitreomacular traction - ocriplasmin NICE TAG TA297
- Choroidal neovascularisation (pathological myopia) - ranibizumab NICE TAG TA298
- Macular oedema (central retinal vein occlusion) - aflibercept solution for injection NICE TAG TA305
- Colorectal cancer (metastatic) - aflibercept NICE TAG TA307
- Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion - NICE TAG TA409
- 11.9 Contact lenses
- 12 Ear, nose, and oropharynx
-
13 Skin
- 13.1 Management of skin conditions
- 13.2 Emollient and barrier preparations
- 13.3 Topical local anaesthetics and antipruritics
- 13.4 Topical corticosteroids
-
13.5 Preparations for eczema and psoriasis
- 13.5.1 Preparations for eczema
- 13.5.2 Preparations for psoriasis
-
13.5.3 Drugs affecting the immune response
- Atopic dermatitis (eczema) - pimecrolimus and tacrolimus - NICE TAG TA82
- Psoriasis - efalizumab and etanercept - NICE TAG TA103
- Psoriasis - infliximab - NICE TAG TA134
- Psoriasis - adalimumab - NICE TAG TA146
- Psoriasis - ustekinumab - NICE TAG TA180
- Psoriatic arthritis - etanercept, infliximab and adalimumab - NICE TAG TA199
- Psoriatic arthritis (active) - ustekinumab NICE TAG TA313
- Ustekinumab for treating active psoriatic arthritis - NICE TAG TA340
- Adalimumab for treating moderate to severe hidradenitis suppurativa - NICE TAG TA392
- Secukinumab for treating moderate to severe plaque psoriasis - NICE TAG TA350
- Apremilast for treating moderate to severe plaque psoriasis- NICE TAG TA419
- Ixekizumab for treating moderate to severe plaque psoriasis - NICE TAG TA442
- Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people - NICE TAG TA455
- Ustekinumab for moderately to severely active Crohn’s disease after previous treatment - NICE TAG TA456
- Brodalumab for treating moderate to severe plaque psoriasis - NICE TAG TA511
- Guselkumab for treating moderate to severe plaque psoriasis - NICE TAG TA521
- Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs - NICE TAG TA537
- Dupilumab for treating moderate to severe atopic dermatitis - NICE TAG TA534
- 13.6 Acne and rosacea
- 13.7 Preparations for warts and calluses
- 13.8 Sunscreens and camouflagers
- 13.9 Shampoos and other preparations for scalp and hair conditions
- 13.10 Anti-infective skin preparations
- 13.11 Skin cleansers, antiseptics, and desloughing agents
- 13.12 Antiperspirants
- 13.13 Topical circulatory preparations
- 14 Immunological products and vaccines
-
15 Anaesthesia
-
15.1 General anaesthesia
- 15.1.1 Intravenous anaesthetics
- 15.1.2 Inhalational anaesthetics
- 15.1.3 Antimuscarinic drugs
- 15.1.4 Sedative and analgesic peri-operative drugs
- 15.1.5 Neuromuscular blocking drugs
- 15.1.6 Drugs for reversal of neuromuscular blockade
- 15.1.7 Antagonists for central and respiratory depression
- 15.1.8 Drugs for malignant hyperthermia
- 15.2 Local anaesthesia
-
15.1 General anaesthesia
- Miscellaneous
-
1 Gastro-intestinal system
- New medicines / ACE
-
Guidelines
- 1. Gastro-intestinal System
- 2. Cardiovascular System Guidelines
- 3. Respiratory System Guidelines
- 4. Central Nervous System Guidelines
- 5. Infections Guidelines
- 6. Endocrine System Guidelines
- 7. Obstetrics, Gynaecology, and Urinary-tract Disorders Guidelines
- 8. Malignant Disease and Immunosuppression Guidelines
- 9. Nutrition and Blood Guidelines
- 10. Musculoskeletal and Joint Diseases Guidelines
- 11. Eye Guidelines
- 12. Ear, Nose, and Oropharynx Guidelines
- 13. Skin Guidelines
- 14. Immunological Products and Vaccines Guidelines
- 15. Anaesthesia Guidelines
-
Shared care
- 1. Gastro-intestinal System Shared Care
- 2. Cardiovascular System Shared Care
- 3. Respiratory System Shared Care
- 4. Central Nervous System Shared Care
- 5. Infections Shared Care
- 6. Endocrine System Shared Care
- 7. Obstetrics, Gynaecology, and Urinary-tract Disorders Shared Care
- 8. Malignant Disease and Immunosuppression Shared Care
- 9. Nutrition and Blood Shared Care
- 10. Musculoskeletal and Joint Diseases Shared Care
- 11. Eye Shared Care
- 12. Ear, Nose, and Oropharynx Shared Care
- 13. Skin Shared Care
- 14. Immunological Products and Vaccines Shared Care
- 15. Anaesthesia Shared Care
- Wound care
- Patient Group Directions (PGDs)
- FAQs
- Further information
- Newsletters
- Referral forms
- Self Care
- Care Homes
- High Cost Drugs
- MTRAC
- COVID-19
13.8.1 Sunscreen preparations
Sun protection products are widely accessible from pharmacies and other retail outlets. See link to Dudley Prescribing Policy